RedHill Biopharma (RDHL) Long-Term Deferred Tax (2017)

RedHill Biopharma (RDHL) has reported Long-Term Deferred Tax for 1 consecutive years, with $76.0 million the latest figure, recorded in Q4 2017.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $76.0 million in Q4 2017; TTM through Dec 2017 was $76.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $76.0 million, changed N/A from the prior year.
• Long-Term Deferred Tax was $76.0 million for Q4 2017 at RedHill Biopharma.
• Over five years, Long-Term Deferred Tax peaked at $76.0 million in Q4 2017 and troughed at $76.0 million in Q4 2017.